Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
01 Sep 2022
01 Sep 2022
Historique:
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Remimazolam is a recently approved benzodiazepine sedative. We report a case of a 72-year-old man who experienced a cardiac arrest due to severe anaphylaxis immediately after general anesthesia induction. Based on the results of skin tests, including those for dextran 40, an excipient in the remimazolam solution, and a review of drugs given during 3 anesthetics, remimazolam was identified as the probable causative agent. Although remimazolam is structurally similar to midazolam, the patient was not allergic to midazolam as demonstrated before and after anaphylaxis. This report highlights the potential risk of allergic reactions to remimazolam.
Identifiants
pubmed: 36149988
doi: 10.1213/XAA.0000000000001616
pii: 02054229-202209000-00007
pmc: PMC9521581
doi:
Substances chimiques
Dextrans
0
Excipients
0
Hypnotics and Sedatives
0
Benzodiazepines
12794-10-4
remimazolam
7V4A8U16MB
Midazolam
R60L0SM5BC
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01616Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Keam SJ. Remimazolam: first approval. Drugs. 2020;80:625–633.
Anerem Interview Form, August 2020. Accessed June 2022. https://mundipharma.co.jp/medical-assets/anerem/anerem-if.pdf (in Japanese).
Kilpatrick GJ, Mclntyre MS, Cox RF, et al. CNS 7056: a novel ultra–short-acting benzodiazepine. Anesthesiology. 2007;107:60–66.
Kilpatrick GJ. Remimazolam: Non-clinical and clinical profile of a new sedative/anesthetic agent. Front Pharmacol. 2021;12:6908075.
Laguna JJ, Archilla J, Doña I, et al. Practical guidelines for perioperative hypersensitivity reactions. J Investig Allergol Clin Immunol. 2018;28:216–232.
Heise Garvey L, Ebo DG, Mertes P-M, Dewachter P, Garcez T. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy. 2019;74:1872–1884.
Tsurumi K, Takahashi S, Hiramoto Y, Nagumo K, Takazawa T, Kamiyama Y. Remimazolam anaphylaxis during anesthesia induction. J Anesth. 2021;35:571–575.
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977; 309:466–469.
Garvey LH, Dewachter P, Hepner DL, et al. Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations. Br J Anaesth. 2019;123:e50–e64.
Simons FER, Ardusso LRF, Bilò MB, et al. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4:13–37.
Scolaro RJ, Crilly HM, Maycock EJ, McAleer PT, Nicholls KA, Rose MA. Australian and New Zealand Anaesthetic Allergy Group perioperative anaphylaxis investigation guidelines. Anaesth Intensive Care. 2017;45:543–555.
Garvey LH, Ebo DG, Krøigaard M, et al. The use of drug provocation testing in the investigation of suspected immediate perioperative allergic reactions: current status. Br J Anaesth. 2019;123:e126–e134.
Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. Immunol Allergy Clin North Am. 2014;34:525–546.